Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides

Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides

State legislatures and pharmacy boards across the country are moving to impose their own restrictions on compounded GLP-1 medications and peptide products, adding a new layer of regulatory complexity for an industry that has already spent the past two years navigating shifting federal guidance. According to a recent analysis published by JD Supra, states are increasingly unwilling to wait for the U.S. Food and Drug Administration to set the outer limits of what compounders, prescribers, and telehealth platforms can do — and many are writing rules that go well beyond the federal regulatory floor.

The development marks a significant shift in how the compounded peptide and weight-loss drug market is likely to be policed going forward. For much of the boom in compounded semaglutide and tirzepatide, the primary regulatory battleground was federal: FDA shortage declarations, warning letters, and enforcement discretion largely dictated what compounding pharmacies could legally produce. That federal-first dynamic appears to be giving way to a patchwork of state-level requirements that companies operating in multiple states will need to track individually.

Why This Matters for the Peptide Industry

Compounded GLP-1 receptor agonists — versions of drugs like semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) prepared by compounding pharmacies rather than manufactured by the brand-name drugmakers — surged in popularity as demand outpaced supply. Under federal law, compounders are generally permitted to prepare copies of FDA-approved drugs when those drugs appear on the FDA's official shortage list, or under other narrower exceptions tied to individual patient need.

As FDA has removed semaglutide and tirzepatide from its shortage lists over the past year, the legal basis for mass compounding of these drugs has narrowed considerably at the federal level. But according to the JD Supra analysis, that narrowing federal pathway has not stopped state activity — if anything, it has intensified it, as states look to fill perceived gaps in oversight of compounding pharmacies, telehealth prescribers, and the broader peptide marketplace, including products marketed outside the traditional GLP-1 category, such as BPC-157 and other research peptides.

For an industry built substantially on compounding pharmacies, medical spas, telehealth platforms, and direct-to-consumer peptide sellers, this state-level activity is not a side issue. It goes to the core question of where and how these businesses can legally operate.

The Regulatory Framework: A Quick Primer

Understanding the stakes requires a basic grasp of how compounding is regulated in the United States:

• 503A pharmacies compound drugs for individual patients pursuant to a specific prescription and are primarily regulated by state boards of pharmacy, with more limited direct FDA oversight.
• 503B outsourcing facilities compound in larger batches without requiring patient-specific prescriptions and are registered with and inspected by FDA under stricter manufacturing standards.
• Both categories rely on drugs being either in shortage or otherwise meeting statutory conditions to compound copies of approved medications like semaglutide or tirzepatide.
• States retain independent authority to license pharmacies, regulate the practice of pharmacy and medicine within their borders, and impose additional restrictions beyond what federal law requires.

It is this last point — the states' independent authority — that is now driving the regulatory action described in the JD Supra report. States are not preempted from imposing stricter rules than the federal baseline, and many are choosing to do exactly that.

What States Are Reportedly Doing

While the specific mechanisms vary by jurisdiction, the broader trend identified in the source reporting includes states using licensing authority, pharmacy practice acts, and consumer protection statutes to impose requirements that exceed federal law. This can involve tightening the conditions under which pharmacies may compound GLP-1 products, increasing scrutiny of telehealth prescribing arrangements that connect out-of-state patients with compounded peptides, and expanding disclosure or labeling obligations aimed at consumer safety.

The result, as the JD Supra piece frames it, is that compliance can no longer be measured solely against FDA's compounding rules. A pharmacy or telehealth company operating nationally may find itself compliant in one state and out of step in another, even while offering an identical product and prescribing process.

What This Means for Industry Stakeholders

• Compounding pharmacies and 503B outsourcing facilities should not assume that federal shortage status or FDA enforcement posture is the final word on legality — state licensing boards may impose additional or different requirements.
• Telehealth companies prescribing compounded GLP-1s or peptides across state lines face a growing need for state-by-state legal review, particularly as more states legislate in this space.
• Investors and business operators evaluating the compounded peptide market should treat regulatory risk as a moving target, not a fixed federal standard.
• Consumers and prescribers alike may see meaningful variation in product availability and prescribing practices depending on the state in which they reside or practice.

In short, the compliance conversation in this sector is shifting from "What does FDA allow?" to "What does FDA allow, and what does each state additionally require?" That is a materially more complicated question for any company operating beyond a single jurisdiction.

What to Watch Next

Industry observers should watch for additional state legislative sessions taking up compounding and telehealth prescribing bills, further guidance or enforcement activity from state pharmacy boards, and any responsive action from FDA as it continues to monitor the compounded GLP-1 and peptide market following the shortage designations' expiration. Litigation or legal challenges testing the boundaries of state authority in this space are also plausible as the regulatory landscape continues to evolve.

Companies operating in this space would be well advised to consult qualified regulatory counsel in each state where they do business, rather than relying on a single federal compliance standard.

This article is for informational purposes only and does not constitute legal advice. Readers with specific compliance questions should consult a qualified attorney licensed in the relevant jurisdiction. This piece is based on reporting from JD Supra; readers are encouraged to consult the original source for additional detail.